Administration of DPP-4 inhibitors to COVID-19 patients with ongoing type 2 diabetes mellitus could be advisable, as they are capable to benefit from effects on glycemic control, but also from protective anti-inflammatory, anti-proliferative and anti-fibrotic effects in the lungs, hearth, and kidneys. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.